RxDoctor Payments Data

Neha Grover, MD

Internal Medicine · Woodbridge, VANPI 1255688701

Payments from drug & device makers

$1,304in general payments, 2019–2025

Across 43 payments — averaging $30.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$664
  • Lilly USA, LLC$152
  • Vanda Pharmaceuticals Inc.$152
  • Exact Sciences$107
  • Pfizer$60
  • AbbVie$51
  • plus $117 from 4 others

What the payments were for

  • Food & beverage$1,304100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,304 in reported general payments places this provider in the 75th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$169,638
Medicare patients
80
Services billed
2,774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$48,170
JardianceEmpagliflozin31$39,127
TrulicityDulaglutide13$13,461
Janumet XrSitagliptin Phos/Metformin Hcl14$9,814
Telmisartan57$936
Atorvastatin Calcium97$884
Rosuvastatin Calcium50$727
Pravastatin Sodium40$685
Montelukast Sodium48$628
Levothyroxine Sodium43$611
Albuterol Sulfate HfaAlbuterol Sulfate18$586
Diclofenac Sodium17$572
Losartan Potassium85$547
Metoprolol Succinate53$460
Gabapentin14$441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$35$48,17042 claims
Lilly USA, LLCTrulicity$152$13,46113 claims
MerckJanumet Xr$17$9,81414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Woodbridge

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →